Neuro-Hitech, Cognitive Improvement From Phase Two Clinical Trial of Huperzine A In Alzheimer's Disease Patients

Feb 06, 2008 - Neuro-Hitech, Inc. (NASDAQ: NHPI), a New York-based biopharmaceutical company focused on developing innovative drugs for the treatment of neurodegenerative diseases, announced top-line results from the double-blind part of a phase 2 clinical trial of Huperzine A in mild to moderate Alzheimer’s disease (AD) patients... Neuro-Hitech's press Release-